Patents by Inventor Shmuel Ben-Sasson

Shmuel Ben-Sasson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220117935
    Abstract: The invention provides carbazole derivatives for the treatment of fibrotic diseases (pathological collagen deposition) in tissues and organs, and related symptoms, and conditions thereof.
    Type: Application
    Filed: November 1, 2021
    Publication date: April 21, 2022
    Inventor: Shmuel BEN-SASSON
  • Publication number: 20220000805
    Abstract: The invention provides synergistic combinations of at least two modulators of MOR, as well as combined compositions, kits methods and uses thereof for treating mental and physical pain, suicidality and depression.
    Type: Application
    Filed: October 29, 2019
    Publication date: January 6, 2022
    Inventors: Yoram YOVELL, Shmuel BEN-SASSON
  • Patent number: 11191748
    Abstract: The invention provides carbazole derivatives for the treatment of fibrotic diseases (pathological collagen deposition) in tissues and organs, and related symptoms, and conditions thereof.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: December 7, 2021
    Assignee: RAZIEL THERAPEUTICS LTD
    Inventor: Shmuel Ben-Sasson
  • Publication number: 20210253511
    Abstract: The present invention provides compounds and methods for the treatment and prevention of diseases and conditions associate with or aggravated by impaired mitophagy.
    Type: Application
    Filed: March 13, 2019
    Publication date: August 19, 2021
    Applicant: Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
    Inventors: Shmuel BEN-SASSON, Einav GROSS
  • Publication number: 20210171604
    Abstract: Short peptides and peptidomimetics useful for treating Type 2 diabetes are provided, and methods for treating and/or preventing Type 2 diabetes and related conditions.
    Type: Application
    Filed: June 10, 2018
    Publication date: June 10, 2021
    Inventor: Shmuel BEN-SASSON
  • Publication number: 20200222364
    Abstract: The invention provides carbazole derivatives for the treatment of fibrotic diseases (pathological collagen deposition) in tissues and organs, and related symptoms, and conditions thereof.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 16, 2020
    Applicant: RAZIEL THERAPEUTICS LTD.
    Inventor: Shmuel BEN-SASSON
  • Patent number: 10632102
    Abstract: The invention provides carbazole derivatives for the treatment of fibrotic diseases (pathological collagen deposition) in tissues and organs, and related symptoms, and conditions thereof.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: April 28, 2020
    Assignee: RAZIEL THERAPEUTICS LTD
    Inventor: Shmuel Ben-Sasson
  • Patent number: 10188659
    Abstract: The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and methods of using these compounds and compositions for the treatment of neurodegenerative diseases, in particular neurodegenerative diseases caused by proteotoxicity such as Alzheimer's disease.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: January 29, 2019
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.
    Inventors: Hadas Reuveni, Ehud Cohen, Alexander Levitzki, Shmuel Ben-Sasson
  • Publication number: 20180169066
    Abstract: The invention provides carbazole derivatives for the treatment of fibrotic diseases (pathological collagen deposition) in tissues and organs, and related symptoms, and conditions thereof.
    Type: Application
    Filed: June 14, 2016
    Publication date: June 21, 2018
    Applicant: RAZIEL THERAPEUTICS LTD.
    Inventor: Shmuel BEN-SASSON
  • Publication number: 20180064725
    Abstract: The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and methods of using these compounds and compositions for the treatment of neurodegenerative diseases, in particular neurodegenerative diseases caused by proteotoxicity such as Alzheimer's disease.
    Type: Application
    Filed: August 24, 2017
    Publication date: March 8, 2018
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.
    Inventors: Hadas REUVENI, Ehud COHEN, Alexander LEVITZKI, Shmuel BEN-SASSON
  • Patent number: 9873724
    Abstract: Short bioactive sequences derived from the 2nd loop of the 7-transmembranal receptor of endothelial differentiation gene 3 (EDG3) useful in stimulation of angiogenesis, and peptide conjugates comprising a permeability enhancing moiety, are provided. Also provided are pharmaceutical compositions comprising the peptides and methods of use in conditions were insufficient blood-supply occurs, or which are associated with endothelia dysfunction such as peripheral vascular diseases, coronary artery diseases, cerebrovascular diseases, diabetes and delayed wound healing, pulmonary disease, eye diseases and pathological condition related to severe infection.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: January 23, 2018
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Shmuel Ben-Sasson, Hadas Reuveni
  • Patent number: 9770454
    Abstract: The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and methods of using these compounds and compositions for the treatment of neurodegenerative diseases, in particular neurodegenerative diseases caused by proteotoxicity such as Alzheimer's disease.
    Type: Grant
    Filed: July 13, 2014
    Date of Patent: September 26, 2017
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
    Inventors: Hadas Reuveni, Ehud Cohen, Alexander Levitzki, Shmuel Ben-Sasson
  • Publication number: 20170106089
    Abstract: This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium. The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.
    Type: Application
    Filed: May 20, 2016
    Publication date: April 20, 2017
    Inventor: Shmuel A. Ben-Sasson
  • Publication number: 20160333070
    Abstract: Short bioactive sequences derived from the 2nd loop of the 7-transmembranal receptor of endothelial differentiation gene 3 (EDG3) useful in stimulation of angiogenesis, and peptide conjugates comprising a permeability enhancing moiety, are provided. Also provided are pharmaceutical compositions comprising the peptides and methods of use in conditions were insufficient blood-supply occurs, or which are associated with endothelia dysfunction such as peripheral vascular diseases, coronary artery diseases, cerebrovascular diseases, diabetes and delayed wound healing, pulmonary disease, eye diseases and pathological condition related to severe infection.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 17, 2016
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Shmuel BEN-SASSON, Hadas REUVENI
  • Patent number: 9447040
    Abstract: Tricyclic compounds, compositions and uses thereof in the treatment of at least one disease, disorder or condition such as for example obesity, overweight, abnormal fat-distribution and any conditions or disease associated therewith.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: September 20, 2016
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Shmuel Ben-Sasson, Arie Dagan, Sharon Perles
  • Publication number: 20160158243
    Abstract: The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and methods of using these compounds and compositions for the treatment of neurodegenerative diseases, in particular neurodegenerative diseases caused by proteotoxicity such as Alzheimer's disease.
    Type: Application
    Filed: July 13, 2014
    Publication date: June 9, 2016
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.
    Inventors: Hadas REUVENI, Ehud COHEN, Alexander LEVITZKI, Shmuel BEN-SASSON
  • Publication number: 20160030568
    Abstract: This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium. The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.
    Type: Application
    Filed: April 22, 2014
    Publication date: February 4, 2016
    Applicant: CHIASMA INC.
    Inventor: Shmuel A. Ben-Sasson
  • Publication number: 20150005252
    Abstract: The present invention provides a combination comprising: a composition comprising at least one non-steroidal anti-inflammatory agent and at least one cytotoxic agent; and a composition comprising at least one ribonucleotide reductase inhibitor. The invention further includes kits comprising a combination of the invention and methods and uses of a combination of the invention for the treatment of cancer treatment of cancer, including solid tumors or tumor metastasis.
    Type: Application
    Filed: January 8, 2013
    Publication date: January 1, 2015
    Inventors: Dafna Feitelberg, Tzivia Berkman, Shmuel Ben-Sasson, Dan Goldstaub
  • Publication number: 20140329877
    Abstract: Tricyclic compounds, compositions and uses thereof in the treatment of at least one disease, disorder or condition such as for example obesity, overweight, abnormal fat-distribution and any conditions or disease associated therewith.
    Type: Application
    Filed: November 15, 2012
    Publication date: November 6, 2014
    Inventors: Shmuel Ben-Sasson, Arie Dagan, Sharon Perles
  • Publication number: 20130157939
    Abstract: The present invention relates to compositions, including pharmaceutical compositions for oral administration, comprising: at least one therapeutically active agent; at least one surface active agent; at least one ester of poly-carboxylic acid and/or at least one ester of an aromatic carboxylic acid; and a non-aqueous medium, for use in the gastric absorption of said at least one therapeutically active agent of the composition and methods of oral administration of at least one therapeutically active agent utilizing compositions of the invention.
    Type: Application
    Filed: August 18, 2011
    Publication date: June 20, 2013
    Inventor: Shmuel Ben-Sasson